Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994688 | 0.77 | SIGMAR1 (0.42) | CALCRLCOMTKMT2AALDH1A1MEN1 | |
| SCHEMBL5775595 | 0.71 | SIGMAR1 (0.50) | COMTALDH1A1MAPTTSHR | |
| SCHEMBL5773487 | 0.71 | SIGMAR1 (0.46) | COMTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL5776436 | 0.70 | SIGMAR1 (0.42) | COMTKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL1290487 | 0.70 | COMT (0.41) | COMTKMT2AALDH1A1MEN1 | |
| SCHEMBL1290485 | 0.70 | HTR1A (0.43) | COMTALDH1A1 | |
| SCHEMBL15648115 | 0.69 | FAAH (0.38) | CALCRLCOMTKMT2AALDH1A1KDM4E | |
| SCHEMBL5778759 | 0.68 | SIGMAR1 (0.46) | COMTALDH1A1 | |
| SCHEMBL1709932 | 0.68 | NPFFR1 (0.45) | KMT2AKDM4EMAPK1 | |
| SCHEMBL5778612 | 0.68 | SIGMAR1 (0.42) | COMTKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CALCRL 1685/4885COMT 2393/4885KMT2A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.